526PD - TRIUMPH: Primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients (pts) with metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) in tumour tissue or circulating tumour DNA (ctDNA): A GOZILA sub-study

Y Nakamura,W Okamoto,T Kato,H Hasegawa,K Kato,S Iwasa,T Esaki,Y Komatsu,T Masuishi,T Nishina,S Nomura,M Fukui,S Matsuda,A Sato,S Fujii,J.I Odegaard,S Olsen,T Yoshino

doi:10.1093/annonc/mdz246.004

526PD - TRIUMPH: Primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients (pts) with metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) in tumour tissue or circulating tumour DNA (ctDNA): A GOZILA sub-study

Y Nakamura, W Okamoto + Show 16 more

Open Access

https://doi.org/10.1093/annonc/mdz246.004

Copy DOI

Journal: Annals of Oncology	Publication Date: Oct 1, 2019
Citations: 33	License type: elsevier-specific: oa user license

Affiliation: National Cancer Center Hospital East, Hiroshima University Hospital, Osaka National Hospital, Hokkaido University, Aichi Cancer Center, Shikoku Cancer Center

#Research Grant #Funding Institution + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

526PD - TRIUMPH: Primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients (pts) with metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) in tumour tissue or circulating tumour DNA (ctDNA): A GOZILA sub-study

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.